# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Acquisition advances Labcorp's specialty testing strategy in key areas such as oncology and rare diseasesKey milestone reac...
Truist Securities analyst Ryan MacDonald maintains Laboratory Corp (NYSE:LH) with a Buy and lowers the price target from $27...
Barclays analyst Stephanie Davis maintains Laboratory Corp (NYSE:LH) with a Equal-Weight and lowers the price target from $2...
Baird analyst Eric Coldwell maintains Laboratory Corp (NYSE:LH) with a Outperform and lowers the price target from $255 to $...
Labcorp beats Q1 sales estimates, driven by organic growth and acquisitions. Revised 2024 guidance projects higher EPS and sale...
Laboratory Corp (NYSE:LH) reported quarterly earnings of $3.68 per share which beat the analyst consensus estimate of $3.48 by ...